600222，控制权或生变！明起停牌

Core Viewpoint - TaLong Pharmaceutical's controlling shareholder is planning to transfer company shares, which may lead to a change in control. The company's stock has been suspended from trading since December 2, 2025, for a period not exceeding two trading days [2][4]. Group 1: Shareholder Information - The controlling shareholder, Zhengzhou TaiRong Industrial Investment Co., Ltd. (TaiRong Investment), holds 82,441,168 shares, accounting for 14.37% of the total shares [9][10]. - The actual controller of TaLong Pharmaceutical is the Zhengzhou High-tech Industrial Development Zone Management Committee, which holds 98.17% of Zhengzhou High-tech Investment Holding Group Co., Ltd. [10]. Group 2: Business Overview - TaLong Pharmaceutical's main business includes drug manufacturing and research services, covering four segments: drug formulation, traditional Chinese medicine pieces, drug research services, and drug material circulation [9]. Group 3: Financial Performance - For the first three quarters, TaLong Pharmaceutical reported a revenue of 1.187 billion yuan, a year-on-year decrease of 11.47%. The net profit attributable to shareholders was 25.33 million yuan, down 12.36% year-on-year [12]. - The company's total revenue for the latest quarter was 1.187 billion yuan, with total costs of 1.167 billion yuan, resulting in an operating profit of 3.5 million yuan [13].